| Jeffrey Alan Messenger, MD | |
|
1515 Lake Lansing Rd Ste A, Lansing, MI 48912-3752 | |
| (517) 487-0128 | |
| Not Available |
| Full Name | Jeffrey Alan Messenger |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 12 Years |
| Location | 1515 Lake Lansing Rd Ste A, Lansing, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427313709 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 4301101373 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bronson Battle Creek Hospital | Battle creek, MI | Hospital |
| Bronson Methodist Hospital | Kalamazoo, MI | Hospital |
| Oaklawn Hospital | Marshall, MI | Hospital |
| Edward W Sparrow Hospital | Lansing, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Midwest Dermatology Institute Pllc | 0244603512 | 2 |
News Archive
Cellegy Pharmaceuticals has announced receipt of a communication from the U.S. Food and Drug Administration in the form of a Not Approvable Letter for its product Cellegesic(TM) (nitroglycerin ointment).
In three studies being presented today during the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, researchers report remarkable benefits from new, more easily administered therapies for bleeding and clotting disorders.
A number of important questions and issues should be addressed before changes are made to the guidelines for the diagnosis of gestational diabetes, according to a new article by University of Maryland School of Medicine Dean E. Albert Reece, M.D., Ph.D., M.B.A., published online in the American Journal of Obstetrics and Gynecology on Oct. 31. The article publishes in advance of a new National Institutes of Health (NIH) initiative to reconsider diagnostic guidelines for the condition.
Essilor has further expanded its presence in fast-growing markets by signing five new partnership agreements in North Africa and Latin America.
A new clinical trial testing a disease-modifying drug for multiple sclerosis will be the first in the world to recognise the importance of wheelchair users retaining the use of their hands.
› Verified 4 days ago
| Entity Name | Compass Healthcare Plc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932533692 PECOS PAC ID: 6002045895 Enrollment ID: O20140127000294 |
News Archive
Cellegy Pharmaceuticals has announced receipt of a communication from the U.S. Food and Drug Administration in the form of a Not Approvable Letter for its product Cellegesic(TM) (nitroglycerin ointment).
In three studies being presented today during the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, researchers report remarkable benefits from new, more easily administered therapies for bleeding and clotting disorders.
A number of important questions and issues should be addressed before changes are made to the guidelines for the diagnosis of gestational diabetes, according to a new article by University of Maryland School of Medicine Dean E. Albert Reece, M.D., Ph.D., M.B.A., published online in the American Journal of Obstetrics and Gynecology on Oct. 31. The article publishes in advance of a new National Institutes of Health (NIH) initiative to reconsider diagnostic guidelines for the condition.
Essilor has further expanded its presence in fast-growing markets by signing five new partnership agreements in North Africa and Latin America.
A new clinical trial testing a disease-modifying drug for multiple sclerosis will be the first in the world to recognise the importance of wheelchair users retaining the use of their hands.
› Verified 4 days ago
| Entity Name | Midwest Dermatology Institute Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649977935 PECOS PAC ID: 0244603512 Enrollment ID: O20230307002700 |
News Archive
Cellegy Pharmaceuticals has announced receipt of a communication from the U.S. Food and Drug Administration in the form of a Not Approvable Letter for its product Cellegesic(TM) (nitroglycerin ointment).
In three studies being presented today during the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, researchers report remarkable benefits from new, more easily administered therapies for bleeding and clotting disorders.
A number of important questions and issues should be addressed before changes are made to the guidelines for the diagnosis of gestational diabetes, according to a new article by University of Maryland School of Medicine Dean E. Albert Reece, M.D., Ph.D., M.B.A., published online in the American Journal of Obstetrics and Gynecology on Oct. 31. The article publishes in advance of a new National Institutes of Health (NIH) initiative to reconsider diagnostic guidelines for the condition.
Essilor has further expanded its presence in fast-growing markets by signing five new partnership agreements in North Africa and Latin America.
A new clinical trial testing a disease-modifying drug for multiple sclerosis will be the first in the world to recognise the importance of wheelchair users retaining the use of their hands.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jeffrey Alan Messenger, MD 1515 Lake Lansing Rd, Lansing, MI 48912-3753 Ph: () - | Jeffrey Alan Messenger, MD 1515 Lake Lansing Rd Ste A, Lansing, MI 48912-3752 Ph: (517) 487-0128 |
News Archive
Cellegy Pharmaceuticals has announced receipt of a communication from the U.S. Food and Drug Administration in the form of a Not Approvable Letter for its product Cellegesic(TM) (nitroglycerin ointment).
In three studies being presented today during the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, researchers report remarkable benefits from new, more easily administered therapies for bleeding and clotting disorders.
A number of important questions and issues should be addressed before changes are made to the guidelines for the diagnosis of gestational diabetes, according to a new article by University of Maryland School of Medicine Dean E. Albert Reece, M.D., Ph.D., M.B.A., published online in the American Journal of Obstetrics and Gynecology on Oct. 31. The article publishes in advance of a new National Institutes of Health (NIH) initiative to reconsider diagnostic guidelines for the condition.
Essilor has further expanded its presence in fast-growing markets by signing five new partnership agreements in North Africa and Latin America.
A new clinical trial testing a disease-modifying drug for multiple sclerosis will be the first in the world to recognise the importance of wheelchair users retaining the use of their hands.
› Verified 4 days ago
Dr. Mark E Hatch, D.O. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 416 S Creyts Rd, Lansing, MI 48917 Phone: 517-886-0333 Fax: 517-886-2072 | |
Yuelin Xu, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1515 Lake Lansing Rd, Suite A, Lansing, MI 48912 Phone: 517-487-0128 Fax: 517-487-2639 | |
Dr. Alice I Gale, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 7201 W Saginaw Hwy, Suite 215, Lansing, MI 48917 Phone: 517-323-2585 Fax: 517-323-2586 | |
Dr. William Frank Heckert, D.O. Dermatology Medicare: Medicare Enrolled Practice Location: 2815 S Pennsylvania Ave, Ste 107, Lansing, MI 48910 Phone: 517-372-2253 Fax: 517-372-2287 | |
Gregory Scott Messenger, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1515 Lake Lansing Rd Ste A, Lansing, MI 48912 Phone: 517-487-0128 Fax: 517-487-2639 | |
Dr. Ronald C Miller, D.O. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 416 S Creyts Rd, Lansing, MI 48917 Phone: 517-886-0333 Fax: 517-886-2072 |